Daniel Hargbøl Madsen

Daniel Hargbøl Madsen serves as Clinical Professor in the Department of Immunology and Microbiology at the University of Copenhagen's Faculty of Health and Medical Sciences. His research focuses on tumor microenvironment dynamics, particularly cancer-associated fibroblasts and immune cell interactions in solid tumors. Based at Blegdamsvej 3B in Copenhagen, he maintains an active research program with significant contributions to cancer immunotherapy.

His primary research interests encompass:

• Tumor microenvironment heterogeneity and stromal remodeling
• Immune checkpoint inhibitor mechanisms and resistance
• Cancer-associated fibroblast biology
• Biomarker discovery for immunotherapy response
• Neuro-immune interactions in tumor progression

Recent work analyzes fibrosis biomarkers, T cell-fibroblast crosstalk, and combination therapies enhancing checkpoint blockade efficacy.

Key scientific contributions include:

• Identification of YKL-40 as a pancreatic cancer prognostic biomarker
• Demonstration of beta-blockers enhancing anti-CTLA4 therapy
• Characterization of arginase-2-specific T cells targeting regulatory T cells
• Development of chitooligosaccharide-based immunotherapy adjuvants

His work shows extensive collaboration with melanoma and pancreatic cancer research groups across Denmark.